Online first
Original article
Published online: 2024-06-13
Comprehensive assessment of Cardiovascular-Kidney-Metabolic (CKM) syndrome: Novel tools for assessment of cardiovascular risk and kidney outcomes in long-term kidney transplant patients
Pubmed: 38887781
Abstract
Not available
References
- Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011; 305(15): 1545–1552.
- Feng X, Hou N, Chen Z, et al. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019. BMJ Open. 2023; 13(3): e064540.
- Małyszko J, Bachorzewska-Gajewska H, Tomaszuk-Kazberuk A, et al. Cardiovascular disease and kidney transplantation‑evaluation of potential transplant recipient. Pol Arch Med Wewn. 2014; 124(11): 608–616.
- Devine PA, Courtney AE, Maxwell AP. Cardiovascular risk in renal transplant recipients. J Nephrol. 2019; 32(3): 389–399.
- Nano J, Schöttker B, Lin JS, et al. Novel biomarkers of inflammation, kidney function and chronic kidney disease in the general population. Nephrol Dial Transplant. 2022; 37(10): 1916–1926.
- Ndumele CE, Rangaswami J, Chow SL, et al. American Heart Association. Cardiovascular-Kidney-Metabolic health: a presidential advisory from the american heart association. Circulation. 2023; 148(20): 1606–1635.
- Jung YuJ, Lee JE, Lee AeS, et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-κB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun. 2012; 419(2): 206–210.
- Kim DH, Jung YuJ, Lee JE, et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol. 2011; 301(2): F427–F435.
- Hosoda R, Nakashima R, Yano M, et al. Resveratrol, a SIRT1 activator, attenuates aging-associated alterations in skeletal muscle and heart in mice. J Pharmacol Sci. 2023; 152(2): 112–122.
- Gu C, Xing Y, Jiang Li, et al. Impaired cardiac SIRT1 activity by carbonyl stress contributes to aging-related ischemic intolerance. PLoS One. 2013; 8(9): e74050.
- Vachharajani VT, Liu T, Wang X, et al. Sirtuins link inflammation and metabolism. J Immunol Res. 2016; 2016.
- Lu CL, Liao MT, Hou YC, et al. Sirtuin-1 and Its Relevance in Vascular Calcification. Int J Mol Sci. 2020; 21(5): 1593.
- He W, Wang Y, Zhang MZ, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010; 120(4): 1056–1068.
- Kida Y, Zullo JA, Goligorsky MS. Endothelial sirtuin 1 inactivation enhances capillary rarefaction and fibrosis following kidney injury through Notch activation. Biochem Biophys Res Commun. 2016; 478(3): 1074–1079.
- Huang XZ, Wen D, Zhang M, et al. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-β/Smad3 pathway. J Cell Biochem. 2014; 115(5): 996–1005.
- Zhao L, Leung LL, Morser J. Chemerin forms: their generation and activity. Biomedicines. 2022; 10(8): 2018.
- Mariani F, Roncucci L. Chemerin/chemR23 axis in inflammation onset and resolution. Inflamm Res. 2015; 64(2): 85–95.
- Behnoush AH, Shobeiri P, Bahiraie P, et al. Chemerin levels in chronic kidney disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023; 14.
- Mocker A, Hilgers KF, Cordasic N, et al. Renal chemerin expression is induced in models of hypertensive nephropathy and glomerulonephritis and correlates with markers of inflammation and fibrosis. Int J Mol Sci. 2019; 20(24): 6240.
- Lin S, Teng J, Li J, et al. Association of chemerin and vascular endothelial growth factor (VEGF) with diabetic nephropathy. Med Sci Monit. 2016; 22: 3209–3214.
- Ferland DJ, Mullick AE, Watts SW. Chemerin as a driver of hypertension: a consideration. Am J Hypertens. 2020; 33(11): 975–986.
- Bekcer GJ, Wheeler DC, Zeeuw DD, et al. Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International Supplements. 2012; 2(5): 337–414.
- Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
- Pattaro C, Riegler P, Stifter G, et al. Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association. Nephron Clin Pract. 2013; 123(1-2): 102–111.
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S): S1–S87.
- SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439–2454.
- Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019; 34(5): 760–773.
- Aziz F, Jorgenson M, Garg N, et al. New approaches to cardiovascular disease and its management in kidney transplant recipients. Transplantation. 2022; 106(6): 1143–1158.
- Zbroch E, Bazyluk A, Malyszko J, et al. The serum concentration of anti-aging proteins, sirtuin1 and αKlotho in patients with end-stage kidney disease on maintenance hemodialysis. Clin Interv Aging. 2020; 15: 387–393.
- Łukawska-Tatarczuk M, Franek E, Czupryniak L, et al. Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease. Biomolecules. 2021; 11(8): 1110.
- Yue XG, Yang ZG, Zhang Y, et al. Correlations between SIRT1 gene polymorphisms and diabetic kidney disease. R Soc Open Sci. 2018; 5(6): 171871.
- Kedenko L, Lamina C, Kedenko I, et al. Genetic polymorphisms at SIRT1 and FOXO1 are associated with carotid atherosclerosis in the SAPHIR cohort. BMC Med Genet. 2014; 15: 112.
- Bielach-Bazyluk A, Zbroch E, Czajkowska K, et al. Serum sirtuin 1 is independently associated with intact PTH among patients with chronic kidney disease. Clin Interv Aging. 2021; 16: 525–536.
- Krekora J, Matuszewska-Brycht O, Sołek J, et al. Sirtuin 1 and Sirtuin 2 Plasma Concentrations in Patients with Ascending Aortic Dissection and Ascending Aortic Aneurysm. Artery Res. 2023; 29(3): 79–82.
- Esmayel IM, Hussein S, Gohar EA, et al. Plasma levels of sirtuin-1 in patients with cerebrovascular stroke. Neurol Sci. 2021; 42(9): 3843–3850.
- Doulamis IP, Tzani AI, Konstantopoulos PS, et al. A sirtuin 1/MMP2 prognostic index for myocardial infarction in patients with advanced coronary artery disease. Int J Cardiol. 2017; 230: 447–453.
- Shao Y, Ren H, Lv C, et al. Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine. 2017; 55(1): 130–138.
- Wang D, Yuan GY, Wang XZ, et al. Plasma chemerin level in metabolic syndrome. Genet Mol Res. 2013; 12(4): 5986–5991.
- Yoo HJ, Choi HY, Yang SJ, et al. Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb. 2012; 19(1): 59–68.
- Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med. 2011; 50(10): 1093–1097.
- Hu W, Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract. 2011; 91(2): 159–163.
- Blaszak J, Szolkiewicz M, Sucajtys-Szulc E, et al. High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction. Ren Fail. 2015; 37(6): 1033–1038.
- Rutkowski P, Sledzinski T, Zielinska H, et al. Decrease of serum chemerin concentration in patients with end stage renal disease after successful kidney transplantation. Regul Pept. 2012; 173(1-3): 55–59.
- Szramowska A, Bielecki M, Grzeszczyk M, et al. High-sensitivity cardiac troponin T in detecting obstructive coronary artery disease in hemodialysis patients listed for kidney transplantation. Kardiol Pol. 2024; 82(3): 285–291.
- Bellasi A, Salera D, Ratti C, et al. Cardiovascular screening in chronic kidney disease subjects waiting for transplantation: Unresolved question. Pol Heart J. 2024; 82(4): 474–476.
- Szramowska A, Bielecki M, Grzeszczyk M, et al. High-sensitivity cardiac troponin T in detecting obstructive coronary artery disease in hemodialysis patients listed for kidney transplantation. Pol Heart J. 2024; 82(3): 285–291.
- Stompór T, Winiarska A. Kidneys in heart failure: Impact of flozins. Kardiol Pol. 2023; 81(11): 1071–1080.
